A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
Phase 1
Recruiting
- Conditions
- Atopic dermatitisTherapeutic area: Diseases [C] - Immune System Diseases [C20]Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Therapeutic area: Phenomena and Processes [G] - Immune system processes [G12]
- Registration Number
- CTIS2022-502888-38-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 262
Inclusion Criteria
Have active atopic dermatitis for over a year and include the following:, EASI score = 12 at first dosing visit, vIGA-AD score =3 at first dosing visit, Have =10% of BSA involvement (per EASI BSA) at first dosing visit, Have little improvement with topical medicines.
Exclusion Criteria
Have any prior skin infections requiring treatment with topical corticosteroids., Have history of psoriasis, Have other infections such as Hepatitis B or C, Known allergy to study drug or any components to formulation or history of drug hypersensitivity reactions.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method